Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1Chondrosarcoma 1

Interventions

Cyclophosphamide 17Rituximab 14Cytarabine 9Peripheral Blood Stem Cell Transplantation 7Melphalan 7Etoposide 7Filgrastim 6Dexamethasone 6fludarabine phosphate 5fludarabine 5Radiotherapy 5Cyclosporine 5Carmustine 5Vincristine 4Prednisone 4Lenalidomide 4Doxorubicin 4Bortezomib 4ibrutinib 3Sensitivity and Specificity 3R-CHOP protocol 3Mycophenolic Acid 3Interferon-alpha 3Indium 3Cisplatin 3Busulfan 3Bendamustine Hydrochloride 3Antilymphocyte Serum 3Antigens, CD19 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Mantle-Cell × TQ-B3525 × Clear all
NCT04398953 2020-09-11

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
102 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡